Disclaimer

The wisdom provided in this clinical reference guide is for informational purposes only. The purpose of this guide is to promote a broad understanding and knowledge of SCN8A in an effort to support clinicians in the care of patients with this rare genetic disorder. It is not intended to be a substitute for published data, clinical practice guidelines, professional medical expertise, diagnosis, or treatment and is useful when corresponding published data are not otherwise available. Always seek the guidance of the contributing physicians with any questions you may have regarding treatment and before beginning a new health care regimen for your patient(s).

Due diligence in research for updates in SCN8A related clinical information is expected before changing treatment course. Never disregard professional medical advice because of something you have read within this reference guide.

The user assumes all responsibility and risk for the use of this guide. Under no circumstances shall The Cute Syndrome Foundation, its volunteers, sponsors, or any contributors to this guide be liable for any DIRECT, INDIRECT, INCIDENTAL, or CONSEQUENTIAL DAMAGES that result from the use of this guide.

Foundation Information & Partnership Opportunities

**Hillary Savoie, PhD**
Founder & Executive Director,
The Cute Syndrome Foundation

foundation@thecutesyndrome.com

Visit scn8a.net

Support Group Referrals

supportgroup@thecutesyndrome.com

SCN8A Clinician Information & Reference Guide

With special thanks to our contributors:

- John Schreiber, MD
- Michael Hammer, PhD
- Juliann Bradish, PharmD
- Manoj Patel, PhD

Discover clinical wisdom about SCN8A from physicians with experience treating this rare disorder.

Learn more about the resources available for your patients with SCN8A.

Visit scn8a.net

Version 3.0
Amended August 2020
### General Information

**SCN8A Mutation Pathology**
- Most concentrated in neural tissue but also found in cardiac tissue
- SCN8A variants associated with epilepsy usually produce a gain-of-function in the voltage-gated channel Nav1.6. In contrast, some loss-of-function variants have been observed and more commonly result in intellectual disability without seizures.

**SCN8A Mutation Onset**
- Age: mean 4 months (Range: birth to >10 years, N=127) ¹
- Seizure type varies
- EEG findings vary from normal or baseline slowing to infantile spasms with or without hypsarrhythmia
- Symptoms range from mild behavioral or movement disorders to severe developmental and cognitive delays

### Symptomatic Treatments

**Drugs of Choice**

**Sodium-channel blockers**
- Patients take 2.4 anti-epileptic drugs on average ²
- Monitor for drug-efficacy **AND** toxicity
- SCN8A epilepsy is commonly drug resistant but has shown a positive response to sodium channel blockers, usually at **supratherapeutic** doses ³
- Seizure control may be related to prognosis
- Those with the best success rates at high dose:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Common Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxcarbazepine</td>
<td>Lacosamide</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Eslicarbazepine</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Ben佐diazepines</td>
</tr>
<tr>
<td>Phenytoin</td>
<td></td>
</tr>
</tbody>
</table>

**Additional Treatments**
- Vitamin D and calcium supplementation—use for Osteopenia prevention
- VNS Therapy—Vagus Nerve Stimulation
- Ketogenic Diet

**Drugs to avoid**
Levetiracetam (Keppra) has been shown to increase seizure severity or have no effect in up to 90% of SCN8A patients. Failure rate = 82%² (makes seizures worse, or no effect) "N=83.”

### Comorbidities

**Consider the following referrals:**
- **Gastroenterology**
  - G-tube dependency, Constipation
- **Pulmonary**
  - Sleep apnea, Laryngomalacia, Pneumonia
- **Orthopedic**
  - Scoliosis
- **Ophthalmology**
  - Cortical Visual Impairment
- **Cardiology (with experience in channelopathies)**
  - Arrhythmias, Bradycardia
- **Physical/Occupational Therapy**
  - Hypotonia, Ataxia, Dyskineties/Movement disorders
- **Speech and Language Pathology**
  - Flaccid Dysarthria, Unsafe swallow, Non-verbal
- **Behavior/Neuropsychology**
  - Autism Spectrum Disorder, ADHD
- **Endocrinology**
  - Osteopenia, Frequent fractures

**Most common comorbidities include:**
constipation, hypotonia, movement disorders/ataxia, high pain tolerance, sleep difficulties, osteopenia and frequent fractures

### Monitoring

**SUDEP**
Genetic epilepsies have a higher risk of Sudden Unexpected/Unexplained Death in Epilepsy (SUDEP). SCN8A specifically may increase the risk of SUDEP possibly due to increased susceptibility of arrhythmias. ⁴
- Consider a seizure monitoring device, pulse oximetry, video/audio monitoring, movement monitors, and antisuffocation pillows in these patients
- Seizures may also cause apnea and prominent autonomic symptoms
- Counsel parents to use on child during sleep
- Encourage parents/caregivers to receive CPR certification

**The presence of either sleep apnea or a bradycardia diagnosis (or both) will aid in insurance approval**

### Genetic Testing

- Consider testing for genetic epilepsy (namely SCN8A) in any patients who have shown an adverse response to levetiracetam, refractory seizures without a known cause, and/or early seizure onset
- Consider SCN8A testing for biological parents to determine if a variant is inherited or de novo
- Refer for genetic counseling if the diagnosis is uncertain or for variants of unknown significance

### Genetic Counseling

Most useful when the diagnosis is uncertain, for variants of unknown significance, and for questions regarding family planning, particularly if a variant is found to be inherited.

### References


**Patients with SCN8A mutations should **NOT** be treated like those with SCN1A mutation or Dravet Syndrome**

---